Rebus Holdings, Inc. (RBSH)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -664 Thousand USD | 35.03% |
| 2021 | -1.02 Million USD | 58.81% |
| 2020 | -2.48 Million USD | -307.39% |
| 2019 | -609 Thousand USD | 15.88% |
| 2018 | -724 Thousand USD | 87.63% |
| 2017 | -5.85 Million USD | -83.42% |
| 2016 | -3.19 Million USD | 47.42% |
| 2015 | -6.06 Million USD | 13.3% |
| 2014 | -6.99 Million USD | -9.43% |
| 2013 | -6.39 Million USD | 6.98% |
| 2012 | -6.87 Million USD | -8.78% |
| 2011 | -6.32 Million USD | -51.46% |
| 2010 | -4.17 Million USD | -18.81% |
| 2009 | -3.51 Million USD | -6.84% |
| 2008 | -3.28 Million USD | -380.43% |
| 2007 | -684.23 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q1 | -134 Thousand USD | -28.85% |
| 2023 Q2 | -109 Thousand USD | 18.66% |
| 2022 FY | -664 Thousand USD | 35.03% |
| 2022 Q1 | -573 Thousand USD | -24.3% |
| 2022 Q3 | -126 Thousand USD | 55.63% |
| 2022 Q2 | -284 Thousand USD | 50.44% |
| 2022 Q4 | -104 Thousand USD | 17.46% |
| 2021 Q1 | -190 Thousand USD | 90.97% |
| 2021 Q2 | -156 Thousand USD | 17.89% |
| 2021 Q3 | -215 Thousand USD | -37.82% |
| 2021 Q4 | -461 Thousand USD | -114.42% |
| 2021 FY | -1.02 Million USD | 58.81% |
| 2020 Q3 | -137 Thousand USD | -19.13% |
| 2020 Q4 | -2.1 Million USD | -1435.77% |
| 2020 FY | -2.48 Million USD | -307.39% |
| 2020 Q1 | -125 Thousand USD | -13.64% |
| 2020 Q2 | -115 Thousand USD | 8.0% |
| 2019 Q1 | -212 Thousand USD | -8.16% |
| 2019 Q4 | -110 Thousand USD | 19.71% |
| 2019 Q2 | -150 Thousand USD | 29.25% |
| 2019 Q3 | -137 Thousand USD | 8.67% |
| 2019 FY | -609 Thousand USD | 15.88% |
| 2018 Q1 | -358 Thousand USD | 88.97% |
| 2018 FY | -724 Thousand USD | 87.63% |
| 2018 Q4 | -196 Thousand USD | -86.67% |
| 2018 Q3 | -105 Thousand USD | -61.54% |
| 2018 Q2 | -65 Thousand USD | 81.84% |
| 2017 FY | -5.85 Million USD | -83.42% |
| 2017 Q4 | -3.24 Million USD | -278.44% |
| 2017 Q3 | -858 Thousand USD | -4.51% |
| 2017 Q2 | -821 Thousand USD | 11.24% |
| 2017 Q1 | -925 Thousand USD | -63.72% |
| 2016 Q2 | -707 Thousand USD | 31.36% |
| 2016 Q1 | -1.03 Million USD | 21.85% |
| 2016 FY | -3.19 Million USD | 47.42% |
| 2016 Q3 | -888 Thousand USD | -25.6% |
| 2016 Q4 | -565 Thousand USD | 36.37% |
| 2015 Q2 | -1.53 Million USD | 16.93% |
| 2015 FY | -6.06 Million USD | 13.3% |
| 2015 Q4 | -1.31 Million USD | 4.08% |
| 2015 Q3 | -1.37 Million USD | 10.25% |
| 2015 Q1 | -1.84 Million USD | -11.23% |
| 2014 Q2 | -1.6 Million USD | 17.22% |
| 2014 FY | -6.99 Million USD | -9.43% |
| 2014 Q3 | -1.79 Million USD | -11.77% |
| 2014 Q4 | -1.65 Million USD | 7.69% |
| 2014 Q1 | -1.94 Million USD | 5.6% |
| 2013 Q1 | -1.53 Million USD | 32.71% |
| 2013 FY | -6.39 Million USD | 6.98% |
| 2013 Q4 | -2.05 Million USD | -53.93% |
| 2013 Q3 | -1.33 Million USD | 9.43% |
| 2013 Q2 | -1.47 Million USD | 3.72% |
| 2012 FY | -6.87 Million USD | -8.78% |
| 2012 Q3 | -1.49 Million USD | 12.19% |
| 2012 Q4 | -2.27 Million USD | -52.31% |
| 2012 Q2 | -1.7 Million USD | -21.12% |
| 2012 Q1 | -1.4 Million USD | 28.26% |
| 2011 Q1 | -808.68 Thousand USD | 39.13% |
| 2011 Q2 | -1.69 Million USD | -109.61% |
| 2011 Q4 | -1.95 Million USD | -5.35% |
| 2011 FY | -6.32 Million USD | -51.46% |
| 2011 Q3 | -1.85 Million USD | -9.63% |
| 2010 Q3 | -579.2 Thousand USD | 61.76% |
| 2010 Q2 | -1.51 Million USD | -101.99% |
| 2010 Q4 | -1.32 Million USD | -129.39% |
| 2010 FY | -4.17 Million USD | -18.81% |
| 2010 Q1 | -749.94 Thousand USD | -23.26% |
| 2009 Q4 | -608.44 Thousand USD | 60.44% |
| 2009 Q2 | -856.24 Thousand USD | -68.15% |
| 2009 FY | -3.51 Million USD | -6.84% |
| 2009 Q1 | -509.21 Thousand USD | 61.86% |
| 2009 Q3 | -1.53 Million USD | -79.63% |
| 2008 Q2 | -506.93 Thousand USD | 3.55% |
| 2008 Q4 | -1.33 Million USD | -45.16% |
| 2008 Q3 | -919.71 Thousand USD | -81.42% |
| 2008 FY | -3.28 Million USD | -380.43% |
| 2008 Q1 | -525.59 Thousand USD | 0.0% |
| 2007 FY | -684.23 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 50.278% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 86.837% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 96.279% |
| Nascent Biotech, Inc. | -2.22 Million USD | 70.223% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.811% |
| Qrons Inc. | -643.67 Thousand USD | -3.157% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -70.444% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 98.804% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -59.816% |
| Skye Bioscience, Inc. | -13.67 Million USD | 95.143% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.075% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 113.51% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -153.7% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.124% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 76.706% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 56.772% |
| Mesoblast Limited | -84.14 Million USD | 99.211% |
| Marizyme, Inc. | -34.08 Million USD | 98.052% |
| Genus plc | 6.4 Million USD | 110.375% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 106.816% |
| Pharming Group N.V. | -4.87 Million USD | 86.392% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 66.574% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 28.708% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 92.048% |
| ContraFect Corporation | -56.88 Million USD | 98.833% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 85.422% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 52.639% |
| IMV Inc. | -38.67 Million USD | 98.283% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 75.862% |
| MultiCell Technologies, Inc. | -722.81 USD | -91763.699% |
| ONE Bio Corp. | 13.68 Million USD | 104.853% |
| Accustem Sciences Inc. | -3.74 Million USD | 82.276% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 98.874% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -37.456% |
| Q BioMed Inc. | -3.44 Million USD | 80.729% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 118.757% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 74.729% |
| Biomind Labs Inc. | -1 Million USD | 34.232% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 98.792% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 77.113% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 90.012% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 64.385% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -2116.88% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 95.816% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 65.642% |
| GB Sciences, Inc. | -1.42 Million USD | 53.256% |
| Alpha Cognition Inc. | -9.7 Million USD | 93.159% |
| HST Global, Inc. | -140.9 Thousand USD | -371.233% |
| CSL Limited | 3.7 Billion USD | 100.018% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 40.973% |
| Halberd Corporation | -75.05 Thousand USD | -784.744% |
| Enzolytics Inc. | -2.14 Million USD | 69.099% |
| Agentix Corp. | -1.37 Million USD | 51.595% |
| Resverlogix Corp. | -12.74 Million USD | 94.792% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 79.042% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.844% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 36.398% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 77.256% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 57.958% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 80.499% |
| AVAX Technologies, Inc. | 6.69 Million USD | 109.921% |
| Zenith Capital Corp. | -8.94 Million USD | 92.575% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.84% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -3711.492% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 72.957% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -287.15% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 66.879% |
| Kadimastem Ltd | -3.04 Million USD | 78.16% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 32.524% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 47.134% |
| BioStem Technologies, Inc. | -7.77 Million USD | 91.464% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -265.87% |
| LadRx Corporation | -3.82 Million USD | 82.634% |
| Cell Source, Inc. | -4.32 Million USD | 84.649% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 3.341% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 3.341% |
| NovAccess Global Inc. | -2.46 Million USD | 73.082% |
| Affymax, Inc. | -15.04 Million USD | 95.587% |
| Itoco Inc. | -919.14 Thousand USD | 27.759% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 84.334% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 40.661% |
| Mobile Lads Corp. | -554.55 Thousand USD | -19.737% |
| CytoDyn Inc. | -18.05 Million USD | 96.323% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -2538.061% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -201.711% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -17.58% |
| SYBLEU INC | -149.18 Thousand USD | -345.1% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 63.443% |
| International Stem Cell Corporation | -663 Thousand USD | -0.151% |
| Bioxytran, Inc. | -3.82 Million USD | 82.618% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1161.398% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -3164.503% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 98.169% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 58.962% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 9.762% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 78.656% |
| Neutra Corp. | -229.48 Thousand USD | -189.342% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 96.214% |
| PureTech Health plc | -146.19 Million USD | 99.546% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 96.91% |
| IXICO plc | -1.43 Million USD | 53.793% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 93.004% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.455% |
| CSL Limited | 3.81 Billion USD | 100.017% |
| Cellectis S.A. | -108.85 Million USD | 99.39% |